



## **vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference**

09/04/19

HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- [vTv Therapeutics Inc.](#) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer's disease, today announced that it is scheduled to present a general company update at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 at 3:00 p.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.

A live webcast of the presentation can be accessed [here](#) and will be accessible for 30 days following the presentation at [www.vtvtherapeutics.com](http://www.vtvtherapeutics.com).

### **About vTv Therapeutics**

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of diabetes, Alzheimer's disease, and inflammatory disorders. vTv's development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.

### **Contacts**

Investors:

vTv Therapeutics Inc.

[IR@vtvtherapeutics.com](mailto:IR@vtvtherapeutics.com)

or

Media:

Josh Vlasto

212-572-5969

[PR@vtvtherapeutics.com](mailto:PR@vtvtherapeutics.com)



Source: vTv Therapeutics Inc.